USP 下的肽复合 795 和 797: 文档

USP 的哪一章管辖您的肽?

多肽合成 范围决定取决于成品制剂在给药时是否必须无菌，而不取决于起始材料是否是肽, 生物制剂, 或小分子.

USP 通则 <795> 用于非无菌混合 适用于给药时制剂不要求无菌的情况: 大多数口服液, 干粉填充, 专题解决方案, 和专门用于体外工作的冻干研究储备液. USP 通则 <797> 用于无菌混合 适用于制剂在给药时必须不含活微生物并符合内毒素限量的情况——注射剂, 眼科, 鞘内制剂, 以及污染造成直接患者或动物安全风险的任何途径.

采购的实际意义是路线和形式必须出现在采购订单中——而不是从顺序推断. 报价前未询问预期用途的供应商无法生成特定于章节的文档包, 因为上表中各行的要求差别很大. 当下游审查批次时，以书面形式记录对话可以保护双方.

身份证明文件: “已确认”对于自定义序列实际上意味着什么

根据 USP 复合逻辑, 身份确认与纯度评估截然不同. 身份回答了一个明确的问题——这是正确的分子吗? — 虽然纯度回答的是定量问题 — 存在多少正确的分子? 仅引用 HPLC 数据作为身份证据是一种记录错误，接受过复合标准培训的检查员通常会将其标记为常规问题.

质谱作为主要身份证据

适用于定制和修饰肽, ESI-MS 或 MALDI-TOF 是公认的身份确认主要方法. 单位分辨率仪器上标准定制序列的接受标准是观察到的 [中+高]⁺或多电荷 [M+nH]ⁿ⁺ 离子在理论单同位素质量的 ±0.5 Da 范围内. 用于高分辨率 ESI-MS 数据, 标准收紧至 ��2 ppm.

CoA 必须报告三项, 没有一个: 理论质量, 观测到的质量, 和测量的增量. 没有支持数字背景的“通过”声明无法重现，也无法被接收实验室的质量控制团队验证.

对于用作内标的同位素标记或富含氘的肽, 需要两个额外的数据点: 同位素包络形状必须符合所宣布的浓缩水平的理论同位素分布, 相对于未标记类似物的 Δ 质量必须落在预期窗口内. 未经包络分析支持的富集声明不能仅通过分子量来确认.

对于聚乙二醇化, 装订的, 或大环肽，其中分子量超过可靠的 MALDI-TOF 范围或电荷包络扩散, 应在 CoA 上的分析方法参考中指定具有光谱解卷积或 MS/MS 碎片离子确认的 LC-MS. 如果供应商的标准平台无法适应分子的复杂性, 这是买方在综合开始之前需要的信息，而不是在 CoA 发布之后.

色谱同一性确认

RP-HPLC 的功能为正交, 证实方法——不是主要方法. 各批次的保留时间重现性, 在同一柱下测量, 流动相, 和梯度条件, 确认材料具有预期的疏水性和保留特性. 这对于检测差向异构化特别有用, 其中 D 残基取代可能产生具有正确分子量但改变保留行为的化合物.

CoA 必须指定: 主峰保留时间, column stationary phase and dimensions, 粒径, 流动相组成 (both aqueous and organic components), gradient program, 流量, column temperature if controlled, 和检测波长. A retention time without method context cannot be reproduced and therefore provides no confirmatory value.

The counterion form introduces a systematic effect that is rarely disclosed without asking. Peptides released from Fmoc SPPS with residual TFA counterion absorb at 214 nm and can produce inflated purity percentages by area normalization relative to the same peptide as the acetate salt. If a lot will be used in cell-based assays — where residual TFA is cytotoxic — the CoA should explicitly confirm counterion exchange and specify the final salt form. This detail belongs in the MFR and the CoA, not in a post-receipt email thread.

修饰肽的纯度标准和 CoA 要求

在综合开始之前定义验收标准

The most avoidable source of lot rejection in custom peptide procurement is a purity specification that was not agreed upon before synthesis commenced. For standard research-grade batches, ≥95% purity by RP-HPLC area normalization is a widely applied acceptance threshold. For material destined for sterile compounding or IND-enabling use, ≥98% purity by HPLC is the industry-typical expectation, though the applicable specification should be documented in the quality agreement rather than assumed. These are industry-typical practice benchmarks, not chapter-mandated numeric limits — which makes their explicit documentation in a purchase-order specification all the more important.

A complete pre-synthesis purity specification for a complex modified peptide should define: (1) minimum main-peak purity by RP-HPLC, (2) maximum acceptable levels for the most probable degradation products — desaminidation, oxidized species at Met or Trp, Asp-Pro bond hydrolysis products, deletion sequences — (3) the endotoxin limit in EU/mg if the compound will be formulated for sterile use, 和 (4) 抗衡离子形式. Writing these down before ordering converts a buyer-preference into a binding quality agreement. Establishing them after delivery converts a buyer’s disappointment into a supplier’s negotiating position.

合规 CoA 必须包含哪些内容

A CoA that does not include the following fields cannot serve as a complete qualification record under USP compounding documentation logic:

A CoA missing any field in this table is incomplete for compounding-level documentation purposes. The appropriate action is to request the missing data before accepting the lot — not to annotate the gap in the receiving record and proceed.

⚠️警告: Accepting an incomplete CoA and documenting the gap in your IMA record does not close the gap for audit purposes. It creates a traceable acknowledgment that the incoming material standard was knowingly not met.

储存条件, 超越用途的约会, 及其背后的稳定性数据

Beyond-use dating is one of the most frequently misunderstood concepts at the supplier-buyer interface. BUD is not expiration dating. Expiration dating is assigned by the original manufacturer under ICH Q1A-compliant stability studies and reflects validated shelf life. BUD is calculated from the date or time of compounding and reflects how long the preparation is expected to retain its composition under specified storage conditions, as established conservatively by the compounder (ASHP, The Pharmacist Guide to Assigning a Beyond-Use Date).

The governing rule for BUD assignment: the BUD must be the earlier of the sterility-based default limit and any shorter limit imposed by a component expiry, ingredient retest date, or documented stability finding. Storage conditions do not extend a BUD beyond ingredient limits — they determine which default BUD category applies when no limiting component constraint exists.

For non-sterile preparations under <795>, the defaults in the absence of supporting stability data are: aqueous solutions, 14 days at controlled cold temperature; non-aqueous liquids and solid formulations, 6 月. For lyophilized peptide powders handled as non-sterile raw materials, a 6-month frozen BUD is defensible only if the container is sealed, desiccated, in inert atmosphere, and held continuously at −20°C or below. Freeze-thaw cycling resets the risk exposure and should trigger documented reassessment.

For sterile preparations under <797>, extended BUD (beyond the 12-hour room-temperature or 24-hour refrigerated defaults for Category 1 通信服务提供商) requires documented stability data from the actual formulation in the actual container-closure system under the actual storage conditions (USP 通则 <797> 常问问题, 2023). A supplier who quotes a 30-day BUD on a sterile peptide solution without a stability study reference is assigning a number, not a scientifically supported date.

Peptide-specific vulnerabilities relevant to storage and BUD decisions include: oxidation at Met, 半胱氨酸, and Trp residues under aerobic conditions; Asp-Pro hydrolysis under acidic conditions and at temperatures above controlled room temperature; aggregation in hydrophobic or disulfide-containing sequences on freeze-thaw cycling; and racemization at certain residues under prolonged refrigeration. These vulnerabilities must be stated in the supplier’s technical dossier — not assumed by the buyer — because they directly affect what storage conditions are appropriate and how conservatively the BUD should be set.

经得起审核的标签要求

The minimum label content for a compounded sterile preparation is specified in USP General Chapter <797>: names and amounts or concentrations of all active ingredients, the BUD (as date, or hour and date where the 4-hour administration window applies), 储存条件, the compounder’s identity, and a clear indication that the preparation is compounded. When the preparation is distributed rather than directly administered, the label must also specify the time period within which administration must begin.

For custom research peptides, the label should additionally carry the sequence identifier or abbreviated modification code. This is particularly important for variant libraries, isotopically labeled analogs, or PEGylation-degree variants where visual inspection provides no basis for discrimination. A label that says “Peptide A, 5 mg/mL” when four structurally related peptides are in storage is not audit-ready for a regulated research environment.

For dry peptide powders released as non-sterile raw materials under <795>, the label content required for your incoming material acceptance SOP is the practical standard: 批号, 顺序, mass or mole quantity, purity result (or CoA reference number), 抗衡离子形式, storage temperature and conditions, and a retest or BUD date. A QR code linking to the digital CoA is a best practice — it reduces transcription error and accelerates IMA review — though it is not a chapter requirement.

每个无菌复合供应商应提供的五份分析记录

For sterile-grade peptide materials, five record categories create the defensible evidence chain from raw ingredient to released lot. Each serves a distinct quality-system function. 集体, they answer the question an auditor must ask: was this lot made correctly, by qualified people, in a controlled environment, and released based on complete data?

1. Master Formula Record (MFR). The MFR is the standing procedure: every ingredient by name and grade, 数量, equipment identification, step-by-step synthesis and processing procedure, in-process acceptance criteria, and quality-control checkpoints. 对于定制肽, the MFR is synthesis-specific — it references resin loading, coupling cycle parameters, 裂解条件, and purification method. It is the reference baseline against which any deviation is evaluated. A deviation without an MFR has no context.

2. Compounding Record (CR) / Batch Record. The CR documents what actually happened for a specific lot: operator identity and date, actual quantities and instruments used, equipment identification, environmental conditions at time of preparation, deviations from the MFR and their disposition, and both operator and second-person verification. The CR is distinct from the MFR — it is lot-specific, not procedure-specific. A lot with only an MFR and no CR has no execution record.

3. Personnel Training and Competency Records. 美国药典 <797> requires documented competency for all personnel involved in sterile compounding, including gloved fingertip and thumb sampling, media-fill qualification, surface sampling, garbing and cleaning competency, and annual or periodic requalification (ASHP Guidelines on Compounding Sterile Preparations, 2014). Training completion certificates are necessary but not sufficient — documented competency assessment results are required.

4. Environmental Monitoring Log. A classified cleanroom designation is a one-time certification; an environmental monitoring log is the ongoing evidence that conditions inside that classification are being maintained. The log must include viable air sampling and surface sampling results, non-viable particle counts, pressure differential readings, temperature and humidity data, action limits for each monitoring location, and documented corrective actions for every exceedance. A log that shows results without action limits cannot be evaluated; a log that shows only non-viable particle data without viable monitoring is incomplete for <797> compliance. The vendor-level supplier governance framework for raw materials and sterilization provides one model for how environmental monitoring connects to lot release decisions.

5. 分析发布记录. These are the source data behind the CoA: the full HPLC chromatogram with integration table, the complete MS spectrum with deconvolution where applicable, the LAL endotoxin assay report including the method standard curve, and the sterility test report where the lot was compounded under sterile conditions. Release records must be retained in retrievable form for a minimum period defined by the applicable quality standard — typically at least 3 years for research-grade material. A qualified supplier should be able to produce these records upon request without requiring a formal audit declaration.

导致检查失败的常见文档缺陷

The deficiencies that appear most predictably in peptide supplier documentation reviews are not complex or unusual. They are standard gaps that process-driven quality systems close routinely — and that documentation-light suppliers never close without external pressure. 关于

BUD assigned without stability data. A 30-day or 90-day BUD on a sterile formulation that references no stability study is an unsupported number. Inspectors ask for the supporting data as a first-line query; “standard industry practice” is not an acceptable reference, and “same compound used elsewhere” is not stability data for your formulation.

CoA missing method reference or column specification. A reported HPLC purity of 98.5% cannot be independently verified without the method. Column stationary phase, dimensions, 粒径, 流动相, 坡度, 流量, 温度, and wavelength must all appear on the CoA or in a method reference document cited by the CoA. If the column has changed between lots, that fact must be documented.

Endotoxin limit not stated. For sterile materials, the CoA must state the acceptance limit (例如, <1 EU/mg or <0.5 欧盟/毫克, depending on the application), the LAL method variant, and the actual result. A result reported without a stated limit leaves the QA team unable to evaluate whether the lot passed the relevant criterion — which is a failing condition in an audit, regardless of the numerical value.

No corrective action documentation for environmental exceedances. An environmental monitoring log that shows an action-limit exceedance with no subsequent corrective action entry indicates either that no investigation was conducted or that it was not documented. Both are problematic. Investigators treat this as a systemic quality failure rather than a record-keeping lapse.

Identity confirmed by chromatography alone. HPLC retention time can corroborate identity but cannot confirm it for custom sequences. Scrambled sequences, racemized residues, and deletion analogs can co-elute under standard RP-HPLC conditions at the expected retention time. MS data is the only method that provides unambiguous molecular identity confirmation for custom sequences; its absence from the CoA is an identity documentation gap, not a purity issue.

使供应商文件与您的内部质量管理体系保持一致

The documentation requirements above are useful only if they map cleanly to your internal quality management system. The most common failure mode is not the absence of supplier records — it is the format mismatch. CoAs with non-standard field labels, batch records in proprietary formats, or analytical reports citing internal method codes without an external translation create friction at incoming material acceptance and extend review timelines for every lot.

The solution is a quality agreement negotiated before the first purchase order, not in response to the first lot rejection. A quality agreement for peptide materials should specify: the exact fields required on the CoA, the format and naming conventions for batch records, the timeframe for providing raw analytical data on request, the process for communicating post-delivery deviations, and record retention obligations. Once in place, it converts your QMS requirements into binding supplier deliverables rather than post-receipt negotiation points.

Three elements are non-negotiable in any quality agreement, regardless of material grade or order volume: a lot-specific CoA with full method references (not a template with a lot number inserted), raw instrument data available on request within a defined window, and a written deviation disclosure process with notification timelines. Establishing these before synthesis begins eliminates most of the downstream quality disputes that consume project time.

For research teams building or reviewing a supplier qualification program, the practical approach to building peptide vendor continuity before a study begins with the quality agreement structure, not with the first CoA review. The incoming material acceptance SOP cannot function as a quality filter if it is only applied after materials have already been produced to an unaligned standard.

For modified or complex custom sequences — PEGylated peptides, cyclic scaffolds, isotope-labeled internal standards — the analytical method selection for identity and purity confirmation requires discussion before synthesis, not after lot release. 这 MOL 改变定制肽合成平台 provides lot-specific CoAs as a standard deliverable, with HPLC chromatograms, 质谱图, and endotoxin LAL reports available on request through the quality documentation process for sterile-grade material. Research teams that need to confirm the full documentation package before committing to a lot can request a lot-specific data review prior to order placement.

If your incoming peptide documentation requirements are not yet fully defined, or if you are managing the transition from a previous supplier with a different documentation standard, the first practical step is a pre-order technical conversation. Contact the MOL Changes synthesis and QC team to align on CoA field requirements, analytical method specifications, and batch record format before synthesis is initiated — it is significantly faster to establish that alignment in writing before a lot exists than to renegotiate it after.